SEOM clinical guideline for treatment of kidney cancer (2017)

被引：18

作者：

Gallardo, E. ^{[1
]}

Mendez-Vidal, M. J. ^{[2
]}

Perez-Gracia, J. L. ^{[3
]}

Sepulveda-Sanchez, J. M. ^{[4
]}

Campayo, M. ^{[5
]}

Chirivella-Gonzalez, I. ^{[6
]}

Garcia-del-Muro, X. ^{[7
]}

Gonzalez-del-Alba, A. ^{[8
]}

Grande, E. ^{[9
]}

Suarez, C. ^{[10
,11
]}

机构：

[1] Univ Autonoma Barcelona, I3PT, Dept Med Oncol, Parc Tauli Hosp Univ, Parc Tauli 1, Sabadell 08208, Spain

[2] Univ Cordoba, Dept Med Oncol, Maimonides Inst Biomed Res IMIBIC, Reina Sofia Hosp, Cordoba, Spain

[3] Clin Univ Navarra, Dept Med Oncol, Pamplona, Spain

[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] Hosp Univ Mutua Terrassa, Dept Med Oncol, Terrassa, Spain

[6] Univ Valencia, Hosp Clin, Dept Med Oncol, Valencia, Spain

[7] Univ Barcelona, Inst Catala Oncol, Dept Med Oncol, Idibell, Lhospitalet De Llobregat, Spain

[8] Hosp Univ Son Espases, Dept Oncol, Palma De Mallorca, Spain

[9] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain

[10] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[11] Univ Autonoma Barcelona, Inst Oncol, Barcelona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 01期

关键词：

Kidney cancer; Systemic therapy; Molecular pathology; RENAL-CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; CYTOREDUCTIVE NEPHRECTOMY; ADJUVANT SUNITINIB; TARGETED THERAPY; OPEN-LABEL; HIGH-RISK; EVEROLIMUS; MULTICENTER;

D O I：

10.1007/s12094-017-1765-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.

引用

页码：47 / 56

页数：10

共 50 条

[1] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[2] Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting [J].

Beuselinck, Benoit ;

Job, Sylvie ;

Becht, Etienne ;

Karadimou, Alexandra ;

Verkarre, Virginie ;

Couchy, Gabrielle ;

Giraldo, Nicolas ;

Rioux-Leclercq, Nathalie ;

Molinie, Vincent ;

Sibony, Mathilde ;

Elaidi, Reza ;

Teghom, Corinne ;

Patard, Jean-Jacques ;

Mejean, Arnaud ;

Fridman, Wolf Herman ;

Sautes-Fridman, Catherine ;

de Reynies, Aurelien ;

Oudard, Stephane ;

Zucman-Rossi, Jessica .

CLINICAL CANCER RESEARCH, 2015, 21 (06) :1329-1339

[3] Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms [J].

Choudhary, S. ;

Rajesh, A. ;

Mayer, N. J. ;

Mulcahy, K. A. ;

Haroon, A. .

CLINICAL RADIOLOGY, 2009, 64 (05) :517-522

[4] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[5] Epidemiology and risk factors for kidney cancer [J].

Chow, Wong-Ho ;

Dong, Linda M. ;

Devesa, Susan S. .

NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257

[6] Comprehensivemolecular characterization of clear cell renal cell carcinoma [J].

Creighton, Chad J. ;

Morgan, Margaret ;

Gunaratne, Preethi H. ;

Wheeler, David A. ;

Gibbs, Richard A. ;

Robertson, A. Gordon ;

Chu, Andy ;

Beroukhim, Rameen ;

Cibulskis, Kristian ;

Signoretti, Sabina ;

Vandin, Fabio ;

Wu, Hsin-Ta ;

Raphael, Benjamin J. ;

Verhaak, Roel G. W. ;

Tamboli, Pheroze ;

Torres-Garcia, Wandaliz ;

Akbani, Rehan ;

Weinstein, John N. ;

Reuter, Victor ;

Hsieh, James J. ;

Brannon, A. Rose ;

Hakimi, A. Ari ;

Jacobsen, Anders ;

Ciriello, Giovanni ;

Reva, Boris ;

Ricketts, Christopher J. ;

Linehan, W. Marston ;

Stuart, Joshua M. ;

Rathmell, W. Kimryn ;

Shen, Hui ;

Laird, Peter W. ;

Muzny, Donna ;

Davis, Caleb ;

Morgan, Margaret ;

Xi, Liu ;

Chang, Kyle ;

Kakkar, Nipun ;

Trevino, Lisa R. ;

Benton, Susan ;

Reid, Jeffrey G. ;

Morton, Donna ;

Doddapaneni, Harsha ;

Han, Yi ;

Lewis, Lora ;

Dinh, Huyen ;

Kovar, Christie ;

Zhu, Yiming ;

Santibanez, Jireh ;

Wang, Min ;

Hale, Walker .

NATURE, 2013, 499 (7456) :43-+

[7] The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma [J].

Davis, Caleb F. ;

Ricketts, Christopher J. ;

Wang, Min ;

Yang, Lixing ;

Cherniack, Andrew D. ;

Shen, Hui ;

Buhay, Christian ;

Kang, Hyojin ;

Kim, Sang Cheol ;

Fahey, Catherine C. ;

Hacker, Kathryn E. ;

Bhanot, Gyan ;

Gordenin, Dmitry A. ;

Chu, Andy ;

Gunaratne, Preethi H. ;

Biehl, Michael ;

Seth, Sahil ;

Kaipparettu, Benny A. ;

Bristow, Christopher A. ;

Donehower, Lawrence A. ;

Wallen, Eric M. ;

Smith, Angela B. ;

Tickoo, Satish K. ;

Tamboli, Pheroze ;

Reuter, Victor ;

Schmidt, Laura S. ;

Hsieh, James J. ;

Choueiri, Toni K. ;

Hakimi, A. Ari ;

Chin, Lynda ;

Meyerson, Matthew ;

Kucherlapati, Raju ;

Park, Woong-Yang ;

Robertson, A. Gordon ;

Laird, Peter W. ;

Henske, Elizabeth P. ;

Kwiatkowski, David J. ;

Park, Peter J. ;

Morgan, Margaret ;

Shuch, Brian ;

Muzny, Donna ;

Wheeler, David A. ;

Linehan, W. Marston ;

Gibbs, Richard A. ;

Rathmell, W. Kimryn ;

Creighton, Chad J. ;

Signoretti, Sabina ;

Seiler, Michael ;

Chao, Hsu ;

Dahdouli, Mike .

CANCER CELL, 2014, 26 (03) :319-330

[8] Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline [J].

Donat, Sherri M. ;

Diaz, Mireya ;

Bishoff, Jay Todd ;

Coleman, Jonathan A. ;

Dahm, Philipp ;

Derweesh, Ithaar H. ;

Herrell, S. Duke, III ;

Hilton, Susan ;

Jonasch, Eric ;

Lin, Daniel W. ;

Reuter, Victor E. ;

Chang, Sam S. .

JOURNAL OF UROLOGY, 2013, 190 (02) :407-416

[9] Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [J].

Dykewicz, CA .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :139-144

[10] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

← 1 2 3 4 5 →